Europe Regenerative Medicines Market Size (2024 - 2029)

The Europe Regenerative Medicine market is anticipated to experience growth driven by the increasing adoption of stem-cell technologies, gene therapies, and tissue engineering, alongside technological advancements in the field. The market's expansion is further supported by a rising demand for stem cell-based products, particularly in response to the COVID-19 pandemic and its impact on treatment approaches. The aging population in Europe, which is more susceptible to chronic diseases, also contributes to the growing need for regenerative medicines. Despite these positive trends, challenges such as regulatory and ethical concerns, along with the high cost of treatments, may impede the market's growth trajectory.

Market Size of Europe Regenerative Medicines Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Europe Regenerative Medicines Market Overview
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 6.40 %

Major Players

Europe Regenerative Medicines Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Europe Regenerative Medicines Market Analysis

The Europe Regenerative Medicines market is expected to grow with a CAGR of 6.4% over the forecast period, (2022-2027)

The outbreak of the COVID-19 pandemic is anticipated to have a significant impact on the regenerative medicines market in Europe. According to the research article published by European Respiratory Journal in June 2020, titled ''Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19, novel therapeutic approaches such as cell-based therapies, especially using mesenchymal stem cells were found to have demonstrated the safety and efficacy in providing effective treatment in patients with acute respiratory distress syndrome (ARDS). Thus, there has been an increasing focus on developing stem cell-based therapies in treating SARS-CoV-2 viral infection. Thus, owing to the aforementioned factors, the studied market is expected to witness a significant impact during the pandemic.

The key factors propelling the growth of the regenerative medicines market in Europe are the increasing adoption of stem-cell technologies, gene therapies, and tissue engineering, and the technological advancements in regenerative medicines.

According to the clinical trial registry as of August 26th, 2022, there were 1,868 clinical trials of stem cell therapy, of which 82 studies were specifically targeted toward regenerative medicines across the world. This is likely to increase the demand for stem cell-based products and regenerative medicines in the market over the next few years. According to the clinicaltrials.gov database, the majority of active recruiting trials are present in Europe. Acute lymphoblastic leukemia (ALL), acute megakaryoblastic leukemia (AML), and acute graft versus host disease (AGHD) are some of the current indications that are primarily being focused upon by the majority of the universities, research centers, and companies. Thus, it is evident that there are growing initiatives associated with stem cells and regenerative medicines, and it is estimated that over the forecast period, the success rate and further approval will rise gradually, which is primarily expected to drive the growth of the market.

Furthermore, according to the United Nations Population Fund's World Population Dashboard's Statistics 2021, Italy has approximately 23.8% of the population aged 65 and above. Thus, the increasing aging population is prone to chronic diseases as a result, demand for regenerative medicines is predicted to rise over the forecast period.

Moreover, as per the article published in August 2022, titled ''European first as County Durham stroke patient, 28, takes part in stem cell treatment trial, a young patient from County Durham is the first in Europe to take part in a new trial to discover whether stem cell treatment can improve recovery from strokes. Such instances are expected to increase the demand for cell therapy, thereby, boosting the growth of the market over the forecast period.

However, regulatory and ethical issues and the high cost of treatments are expected to hinder the growth of the market.

Europe Regenerative Medicines Industry Segmentation

As per the scope of this report, regenerative medicines are used to repair, replace, and regenerate the tissues and organs affected by injury, disease, or the natural aging process. These medicines restore the functionality of cells and tissues and are used in several degenerative disorders, such as dermatology, neurodegenerative diseases, cardiovascular, and orthopedic applications. The Europe Regenerative Medicines market is segmented by Type of Technology, Application, and Geography. By Type of Technology, the market is segmented into Stem Cell Therapy, Biomaterial, Tissue Engineering, and Other Types of Technologies. By Application, the market is segmented into Bone Graft Substitutes, Osteoarticular Diseases, Dermatology, Cardiovascular, Central Nervous System, and Other Applications. By Geography, the market is segmented into Germany, United Kingdom, France, Italy, Spain, and Rest of Europe. The report offers the value (in USD million) for the above segments.

By Type of Technology
Stem Cell Therapy
Biomaterial
Tissue Engineering
Other Types of Technologies
By Application
Bone Graft Substitutes
Osteoarticular Diseases
Dermatology
Cardiovascular
Central Nervous System
Other Applications
By Geography
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region Or Segment?
Customize Now

Europe Regenerative Medicines Market Size Summary

The Europe regenerative medicines market is poised for significant growth, driven by advancements in stem cell technologies, gene therapies, and tissue engineering. The market is experiencing increased interest due to the COVID-19 pandemic, which highlighted the potential of cell-based therapies, particularly mesenchymal stem cells, in treating severe respiratory conditions. This has spurred research and development in stem cell-based treatments, contributing to the market's expansion. The aging population in Europe, particularly in countries like Italy, is also a key factor, as the demand for regenerative medicines rises with the prevalence of chronic diseases. Additionally, ongoing clinical trials and research initiatives across Europe are expected to enhance the success rates and approvals of regenerative therapies, further propelling market growth.

France is anticipated to lead the market due to its adoption of innovative therapies and substantial investments in healthcare infrastructure. The country's focus on standardizing orthobiologic treatments and expanding facilities for cell and gene therapy manufacturing is expected to bolster the market. The presence of major global players in Europe, such as Abbvie Inc., Medtronic plc, and Merck KGaA, contributes to a competitive landscape, facilitating the accessibility of regenerative medicines. Regulatory approvals, like those for CAR T-cell therapies, and collaborations aimed at improving patient outcomes are also key drivers of market growth. Despite challenges such as regulatory and ethical concerns, the market is set to expand, supported by technological advancements and increasing demand for regenerative treatments.

Explore More

Europe Regenerative Medicines Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Adoption of Stem-cell Technology

      2. 1.2.2 Technological Advancements in Regenerative Medicines

    3. 1.3 Market Restraints

      1. 1.3.1 Regulatory and Ethical Issues

      2. 1.3.2 High Cost of Treatments

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Type of Technology

      1. 2.1.1 Stem Cell Therapy

      2. 2.1.2 Biomaterial

      3. 2.1.3 Tissue Engineering

      4. 2.1.4 Other Types of Technologies

    2. 2.2 By Application

      1. 2.2.1 Bone Graft Substitutes

      2. 2.2.2 Osteoarticular Diseases

      3. 2.2.3 Dermatology

      4. 2.2.4 Cardiovascular

      5. 2.2.5 Central Nervous System

      6. 2.2.6 Other Applications

    3. 2.3 By Geography

      1. 2.3.1 Germany

      2. 2.3.2 United Kingdom

      3. 2.3.3 France

      4. 2.3.4 Italy

      5. 2.3.5 Spain

      6. 2.3.6 Rest of Europe

Europe Regenerative Medicines Market Size FAQs

The Europe Regenerative Medicines Market is projected to register a CAGR of 6.40% during the forecast period (2024-2029)

Merck KGaA, Integra LifeSciences Corporation, Cook Biotech Incorporated, Thermo Fisher Scientific and Smith & Nephew (Osiris Therapeutics) are the major companies operating in the Europe Regenerative Medicines Market.

Europe Regenerative Medicine Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)